A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Summary

This was a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.

Timeline

Start

2024-04-10

Primary completion

2024-08-27

Completion

2024-08-27

Drugs

Indications